ITCI: intracellulartherapies.com Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The visualization of Intra-Cellular Therapies (ITCI) market value demonstrates a figure of . The business is based on developing schizophrenia treatments that are becoming the gold standard of therapy and guaranteeing stable sales for years. Demand for such medications is independent of market cycles or seasonality, ensuring high resilience. Meanwhile, Intra-Cellular Therapies (ITCI) maintains a staff of CNS experts and is actively recruiting sales representatives.
Summary analytical data breakdowns for intracellulartherapies.com (ITCI)
- stock price and consensus target price:
- market capitalization information:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Intra-Cellular Therapies|ITCI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Intra-Cellular Therapies, Inc.|ITCI - Company Cumulative Debt|Debt to Book Capitalization Ratio Intra-Cellular Therapies, Inc.|ITCI - Company Long-Term Debt|Company Short-Term Debt Intra-Cellular Therapies|Quick Liquidity Indicator intracellulartherapies.com
- financial results and valuation multiples details:
ITCI - Net Profit|Expected Profit Intra-Cellular Therapies|ITCI - Price to Earnings Ratio|Forward P/E Multiple Intra-Cellular Therapies, Inc.|ITCI - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intra-Cellular Therapies, Inc.|ITCI - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Intra-Cellular Therapies|ITCI - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months intracellulartherapies.com|ITCI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Intra-Cellular Therapies
Initial company analysis:ITCI (Intra-Cellular)
Steady demand for the drug Caplyta gives Intra-Cellular Therapies (ITCI) defensive qualities, highlighting the significance of the EV/EBITDA metric including depreciation and debt. This metric correlates the total enterprise value with operating profit, neutralizing the impact of the tax burden and borrowing structure. The trend in EV/EBITDA including depreciation and debt allows for an objective assessment of the company's capitalization efficiency relative to its actual cash flow.
Who Intra-Cellular Therapies competes with
Biogen Corp - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NBIX (Neurocrine Corp)|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AXSM (axsome.com)|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio VKTX|SUPN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CPRX|Enterprise Value to EBITDA Ratio denalitherapeutics.com DNLI|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Biohaven Ltd (BHVN) - Company Value to EBITDA|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AVXL (anavex.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CBLL|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANNX (Annexon Biosciences Inc.)|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VYGR (Voyager Therapeutics Inc)|NMRA (Neumora Therapeutics Inc) - Enterprise Value to EBITDA Ratio|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TVGN|ACOG (Alpha Cognition Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|IKT (Inhibikase Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VTGN (Vistagen Therapeutics)|OVID: EV/EBITDA Multiple|Acumen Pharmaceuticals Inc. (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Alterity Therapeutics Ltd - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|Total Company Value to Operating Income Before Depreciation Ratio pepgen.com|EV/EBITDA Multiple JUNS (Jupiter Neurosciences)|Relmada Therapeutics Inc (RLMD) - Company Value to EBITDA|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Grace Therapeutics, Inc. GRCE|AIFF: EV/EBITDA Multiple|KLTO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NRSN|RVPH (Reviva Pharmaceuticals Holdings Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple MTVA|Enterprise Value to EBITDA Ratio NeurAxis Inc NRXS|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio Inc. (PASG)|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NERV (Minerva Neurosciences Inc) - Enterprise Value to Operating Income Before Depreciation|ATHA: EV/EBITDA Multiple|Company Value to EBITDA Addex (ADXN)|Enterprise Value to EBITDA Ratio ALZN|EV/EBITDA Multiple Cyclerion|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cortigent CRGT|Avenue Therapeutics Inc (ATXI) - Company Value to EBITDA|Brainstorm Cell - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio caratherapeutics.com CARA|Chromocell Therapeutics Corp. (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ELYM|Enterprise Value to EBITDA Ratio LBPH|MRNS (Marinus Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Vigil Neuroscience (VIGL)|WENA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cerevel.com
